Austco Healthcare's Explosive Growth Hits a Supply Chain Wall

Record early growth and margins gave way to supply chain disruptions and hospital construction delays that shrank the contracted backlog and forced a downgrade.

31 Aug 2026 · 3 min read

Austco Healthcare, a technology-enabled healthcare communications and clinical workflow provider, delivered explosive early growth with revenue up 51 percent and record margins, before supply chain disruptions and hospital construction delays forced a weaker second half, shrinking its contracted backlog and pulling the stock down more than 40 percent.

Explosive early growth in a structurally growing market

Tamim Funds Management described Austco Healthcare as a technology-enabled healthcare solutions provider operating in an industry experiencing rapid demand growth, with ageing populations, increasing staffing pressures and rising expectations for care quality driving hospitals and aged care facilities to invest, reporting a strong first-quarter FY26 with revenue up 51 percent to $23.2 million, driven by both organic and acquisition-led growth, with EBITDA rising to $4.2 million, an 18.1 percent margin up from 16.0 percent at FY25 year-end, reflecting operating leverage and integration benefits, with unfilled contracted revenue at $54.6 million supporting future momentum. DMX Asset Management said Austco reported a 71 percent increase in EBITDA on the back of the 51 percent revenue increase, estimating organic revenue growth above 20 percent, with the order book increasing to around $55 million supporting continued momentum. Merewether Capital said the first-quarter AGM update showed revenue up 51 percent and EBITDA of $4.2 million driven by a record margin, with acquisitions the main driver of headline numbers but management targeting 10 to 14 percent organic growth, putting the company on track for $11 million to $12 million net profit in FY26 given a seasonally stronger second half.

Austco Healthcare reported a 71% increase in EBITDA on the back of a 51% increase in revenue and a 2% uplift in its EBITDA margin to 18%. We estimate organic revenue growth to be more than 20%. Importantly, AHC has seen an increase in its order book to ~$55m which supports strong continued momentum.

— DMX Asset Management, Monthly Report, October 2025

A shrinking backlog signals trouble ahead

Merewether Capital said Austco reported revenue up 31 percent to $48.2 million and net profit up 62 percent to $4.8 million, with a traditional seasonal skew to the second half keeping it on track for $11 million to $12 million net profit against an enterprise value of roughly $115 million, though the only negative in the result was the contracted backlog falling from $55 million at the October AGM update to $47 million.

The only negative of the result was the contracted backlog falling from $55m at the AGM update in October last year to $47m now.

— Merewether Capital, Monthly Report, February 2026

Supply chain disruption and construction delays force a downgrade

DMX Asset Management said the stock fell 18 percent on a downgrade, with the company citing supply chain disruptions and hospital construction delays affecting the timing of nurse calling system sales, believing the deterioration in the order book was weighing on shares as Austco lost some of the COVID-era capital spend tailwind that had previously supported it. Merewether Capital said a weaker than expected trading update reflected tough conditions in the second half from disrupted supply chains and semiconductor shortages, though full-year numbers remained positive with revenue growth of 14 percent and EBITDA growth of 10 percent, leaving the stock, at a $90 million market cap with $15 million of net cash, trading on less than 8 times the annualised weak second-half earnings.

At a $90m market cap with $15m net cash on the balance sheet, AHC trades on less than 8x the annualised weak 2H earnings.

— Merewether Capital, Investor Update, June 2026

What fund managers say they are watching next is whether the contracted backlog stabilises and rebuilds from its current $47 million level, resolution of semiconductor supply shortages affecting nurse calling system deliveries, whether hospital construction delays ease, and whether the stock's now-cheap, net-cash-backed valuation proves an entry point once supply chain issues resolve.